JP2019500870A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500870A5 JP2019500870A5 JP2018529539A JP2018529539A JP2019500870A5 JP 2019500870 A5 JP2019500870 A5 JP 2019500870A5 JP 2018529539 A JP2018529539 A JP 2018529539A JP 2018529539 A JP2018529539 A JP 2018529539A JP 2019500870 A5 JP2019500870 A5 JP 2019500870A5
- Authority
- JP
- Japan
- Prior art keywords
- vhl
- targeting
- loss
- function
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307050 | 2015-12-18 | ||
| EP15307050.3 | 2015-12-18 | ||
| PCT/EP2016/081485 WO2017103147A1 (en) | 2015-12-18 | 2016-12-16 | Method for assessing the response to pd-1/pdl-1 targeting drugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500870A JP2019500870A (ja) | 2019-01-17 |
| JP2019500870A5 true JP2019500870A5 (https=) | 2019-12-19 |
| JP6762363B2 JP6762363B2 (ja) | 2020-09-30 |
Family
ID=55129471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529539A Active JP6762363B2 (ja) | 2015-12-18 | 2016-12-16 | Ｐｄ−１／ｐｄｌ−１を標的とする薬物に対する応答を評価する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11137404B2 (https=) |
| JP (1) | JP6762363B2 (https=) |
| KR (1) | KR102378298B1 (https=) |
| IL (1) | IL260024B (https=) |
| WO (1) | WO2017103147A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101980003B1 (ko) * | 2017-09-14 | 2019-05-17 | 건국대학교 글로컬산학협력단 | 면역체크포인트의 발현을 억제하기 위한 물질을 포함하는 나노입자 전달체 |
| KR102216725B1 (ko) * | 2017-12-29 | 2021-02-17 | 연세대학교 산학협력단 | 면역 항암 요법에 대한 치료 반응 예측 방법 |
| WO2019159825A1 (ja) * | 2018-02-14 | 2019-08-22 | 国立大学法人名古屋大学 | 抗ｐｄ－１抗体／抗ｐｄ－ｌ１抗体療法の効果を予測するバイオマーカー |
| GB201805876D0 (en) * | 2018-04-09 | 2018-05-23 | Francis Crick Institute Ltd | Method |
| JP2022533012A (ja) * | 2019-04-30 | 2022-07-21 | エックスセル・バイオサイエンシズ・インコーポレイテッド | 細胞表現型を調節するための系および方法 |
| WO2020239558A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| KR20230125672A (ko) * | 2022-02-21 | 2023-08-29 | 사회복지법인 삼성생명공익재단 | 암 환자에 대한 면역관문억제제의 반응성 예측용 조성물 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
-
2016
- 2016-12-16 JP JP2018529539A patent/JP6762363B2/ja active Active
- 2016-12-16 US US16/061,667 patent/US11137404B2/en not_active Expired - Fee Related
- 2016-12-16 WO PCT/EP2016/081485 patent/WO2017103147A1/en not_active Ceased
- 2016-12-16 KR KR1020187020429A patent/KR102378298B1/ko active Active
-
2018
- 2018-06-14 IL IL260024A patent/IL260024B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500870A5 (https=) | ||
| Zhou et al. | Clinical impact of molecular subtyping of pancreatic cancer | |
| Colucci et al. | Senescence in cancer | |
| Zhang et al. | TGF-β signaling and resistance to cancer therapy | |
| Casadei et al. | Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors | |
| MacKenzie Jr et al. | ALT positivity in human cancers: prevalence and clinical insights | |
| Heidegger et al. | Targeting the tumor microenvironment in renal cell cancer biology and therapy | |
| Sauer et al. | Innovative approaches in the battle against cancer recurrence: novel strategies to combat dormant disseminated tumor cells | |
| Chen et al. | Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis | |
| Patel et al. | Generation of diffuse intrinsic pontine glioma mouse models by brainstem-targeted in utero electroporation | |
| Jahangiri et al. | Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance | |
| Wu et al. | Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches | |
| Linger et al. | Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors | |
| Steuer et al. | Innovative clinical trials: the LUNG‐MAP study | |
| Zerbini et al. | Computational repositioning and preclinical validation of pentamidine for renal cell cancer | |
| Machnicki et al. | BRAF—a new player in hematological neoplasms | |
| Wang et al. | CRKL promotes cell proliferation in gastric cancer and is negatively regulated by miR-126 | |
| Braunstein et al. | Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer | |
| Greil et al. | Reactivation of dormant anti-tumor immunity–a clinical perspective of therapeutic immune checkpoint modulation | |
| He et al. | Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations | |
| Saltiki et al. | MANAGEMENT OF ENDOCRINE DISEASE: medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives | |
| Rappold et al. | Immune checkpoint blockade in renal cell carcinoma | |
| Li et al. | MiR-199a inhibits tumor growth and attenuates chemoresistance by targeting K-RAS via AKT and ERK signalings | |
| Hovsepyan et al. | Desmoplastic small round cell tumor: from state of the art to future clinical prospects | |
| Zhang et al. | PP2AC level determines differential programming of p38-TSC-mTOR signaling and therapeutic response to p38-targeted therapy in colorectal cancer |